- In February 2024, Beigene's Zanubrutinib received approval in Canada for treating Relapsed or Refractory Follicular Lymphoma (FL) in combination with obinutuzumab. This expands its indications beyond previously approved uses, including Waldenström's macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL), marking a significant step in broadening its therapeutic scope
- In November 2023, Novartis announced that its oral Bruton’s tyrosine kinase inhibitor, remibrutinib, demonstrated substantial symptom relief for chronic spontaneous urticaria in Phase III trials. Improvement was observed as early as Week 2, showcasing a favorable safety profile. Ongoing studies are expected to further explore its potential and solidify its efficacy in managing this condition
- In August 2022, The FDA approved the tablet formulation of Calquence (acalabrutinib) for treating adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory mantle cell lymphoma (MCL). The approval was granted under accelerated approval, highlighting its potential in providing effective treatment options for these cancers and improving patient outcomes
